Literature DB >> 32627269

Endothelin-1 in the pathophysiology of obesity and insulin resistance.

Haley N Jenkins1, Osvaldo Rivera-Gonzalez1, Yann Gibert2, Joshua S Speed1.   

Abstract

The association between plasma endothelin-1 (ET-1) and obesity has been documented for decades, yet the contribution of ET-1 to risk factors associated with obesity is not fully understood. In 1994, one of first papers to document this association also noted a positive correlation between plasma insulin and ET-1, suggesting a potential contribution of ET-1 to the development of insulin resistance. Both endogenous receptors for ET-1, ETA and ETB are present in all insulin-sensitive tissues including adipose, liver and muscle, and ET-1 actions within these tissues suggest that ET-1 may be playing a role in the pathogenesis of insulin resistance. Further, antagonists for ET-1 receptors are clinically approved making these sites attractive therapeutic targets. This review focuses on known mechanisms through which ET-1 affects plasma lipid profiles and insulin signalling in these metabolically important tissues and also identifies gaps in our understanding of ET-1 in obesity-related pathophysiology.
© 2020 World Obesity Federation.

Entities:  

Keywords:  ET-1; insulin resistance; obesity

Year:  2020        PMID: 32627269      PMCID: PMC7669671          DOI: 10.1111/obr.13086

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  82 in total

1.  Endothelin-1 stimulates leptin production in adipocytes.

Authors:  Y Xiong; H Tanaka; J A Richardson; S C Williams; C A Slaughter; M Nakamura; J L Chen; M Yanagisawa
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

2.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

Review 3.  Mechanisms of adiponectin regulation and use as a pharmacological target.

Authors:  Susan A Phillips; Jacqueline T Kung
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

Review 4.  Insulin resistance syndrome: possible key role of blood flow in resting muscle.

Authors:  P O Ganrot
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

5.  Endothelin-1 induces lipolysis in 3T3-L1 adipocytes.

Authors:  Chi-Chang Juan; Chih-Ling Chang; Ying-Hsiu Lai; Low-Tone Ho
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-01-25       Impact factor: 4.310

6.  Leptin induces endothelin-1 in endothelial cells in vitro.

Authors:  Peter Quehenberger; Markus Exner; Raute Sunder-Plassmann; Katharina Ruzicka; Christian Bieglmayer; Georg Endler; Claudia Muellner; Wolfgang Speiser; Oswald Wagner
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

Review 7.  Synthesis and degradation of endothelin-1.

Authors:  P D'Orléans-Juste; M Plante; J C Honoré; E Carrier; J Labonté
Journal:  Can J Physiol Pharmacol       Date:  2003-06       Impact factor: 2.273

8.  Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: relationship with hepatic hemodynamics.

Authors:  A Leivas; W Jiménez; J Bruix; L Boix; J Bosch; V Arroyo; F Rivera; J Rodés
Journal:  J Vasc Res       Date:  1998 May-Jun       Impact factor: 1.934

9.  Editorial: "Linking Hypoxia to Obesity".

Authors:  Daniela P Foti; Antonio Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-22       Impact factor: 5.555

Review 10.  Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.

Authors:  Ralph A DeFronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more
  6 in total

1.  Correlation of NO and ET-1 Levels with Blood Pressure Changes in Hemodialysis Patients after Arteriovenous Fistula Surgery.

Authors:  Yanli Li; Hanxiao Lu; Yu Sun
Journal:  Front Surg       Date:  2022-05-16

2.  Dual endothelin receptor antagonism increases resting energy expenditure in people with increased adiposity.

Authors:  Cassandra C Derella; Anson M Blanks; Andy Nguyen; Jacob Looney; Matthew A Tucker; Jinhee Jeong; Paula Rodriguez-Miguelez; Jeffrey Thomas; Matthew Lyon; David M Pollock; Ryan A Harris
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-04-04       Impact factor: 5.900

3.  Proteostasis Response to Protein Misfolding in Controlled Hypertension.

Authors:  Manuel Teixeira; Dário Trindade; Marisol Gouveia; Roberta Eller-Borges; Sandra Magalhães; Ana Duarte; Miriam Ferreira; Maria I Simões; Maria Conceição; Alexandra Nunes; Ana Gabriela Henriques; Fernando Ribeiro; Sandra I Vieira
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

4.  Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium.

Authors:  Chaterina Sujana; Veikko Salomaa; Frank Kee; Jochen Seissler; Pekka Jousilahti; Charlotte Neville; Cornelia Then; Wolfgang Koenig; Kari Kuulasmaa; Jaakko Reinikainen; Stefan Blankenberg; Tanja Zeller; Christian Herder; Ulrich Mansmann; Annette Peters; Barbara Thorand
Journal:  Cardiovasc Diabetol       Date:  2022-06-09       Impact factor: 8.949

5.  Pathological Hyperinsulinemia and Hyperglycemia in the Impaired Glucose Tolerance Stage Mediate Endothelial Dysfunction Through miR-21, PTEN/AKT/eNOS, and MARK/ET-1 Pathways.

Authors:  Ran Liu; Shilin Guan; Zhongai Gao; Jingyu Wang; Jie Xu; Zhaohu Hao; Yi Zhang; Shaohua Yang; Zhenhong Guo; Juhong Yang; Hailin Shao; Baocheng Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

6.  Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice.

Authors:  Li Feng; Songhua Wang; Feng Chen; Cheng Zhang; Qiao Wang; Yuting Zhao; Zifeng Zhang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-02       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.